logo
Bernard Kerik, New York police chief through 9/11, dead at 69

Bernard Kerik, New York police chief through 9/11, dead at 69

Malay Mail2 days ago

NEW YORK, May 30 — Bernard 'Bernie' Kerik, who rose to national prominence after leading the New York police department through the September 11 terror attacks, died yesterday. He was 69.
FBI Director Kash Patel announced Kerik's death on X, saying he passed away 'after a private battle with illness.'
Lauding Kerik, Patel called him 'a warrior, a patriot and one of the most courageous public servants this country has ever known.'
Kerik was the tough-talking head of the New York police when Osama bin Laden's hijackers struck the World Trade Center towers with commercial passenger jets in September 2001.
In the traumatic days and weeks after the attack, Kerik, with his squat, muscular build, balding head and black moustache, became a familiar face to Americans across the country, as he helped then-mayor Rudy Giuliani guide New York through the crisis.
He'd served as Police Commissioner for less than a year when his life and career were altered forever by the terror attacks that killed nearly 2,750 people, including 23 NYPD officers.
When Giuliani's second term ended shortly after the attacks, Kerik left office with him and continued their decades-long friendship and professional allegiance.
Kerik's rough upbringing was detailed in a memoir, 'The Lost Son: A Life in Pursuit.' Born in New Jersey to an alcoholic prostitute, he was abandoned by his mother and brought up by his father, and had a troubled childhood.
Early on his career took him around the world, with a spell on a military police posting in South Korea and working as a security consultant for the Saudi royal family in Saudi Arabia.
He later joined the New York Police Department, where he worked undercover in the narcotics division and helped bust 60 members of the notorious Colombian Cali drug cartel.
After leaving the Police Commissioner role post-9/11, Kerik stayed active in Republican politics, taking on a tour of duty to Iraq to help train their law enforcement in 2003 for former president George W. Bush.
He suffered another fall from grace after pleading guilty in 2009 to felonies, including tax fraud.
He admitted to accepting US$255,000 worth of renovations to his apartment from a construction firm—suspected of having mob ties—angling for government contracts.
His plea helped him avoid a maximum potential sentence of up to 61 years behind bars.
Instead, he was sentenced to four years in prison. He was released in 2013.
Kerik received a presidential pardon in 2020, during President Donald Trump's first term.
He later teamed up with Giuliani to investigate debunked allegations of election fraud following Trump's 2020 loss, and was among those subpoenaed by lawmakers over accusations of plotting to overturn the election in the January 6, 2021, attacks on the US Capitol. — AFP

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US FDA approves Moderna's next-gen Covid vaccine
US FDA approves Moderna's next-gen Covid vaccine

Free Malaysia Today

time7 hours ago

  • Free Malaysia Today

US FDA approves Moderna's next-gen Covid vaccine

Moderna's CEO Stephane Bancel said the approval provides a key tool to protect those at high risk of severe Covid-19. (EPA Images pic) CAMBRIDGE : The US food and drug administration has approved Moderna's next-generation Covid-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from Covid-19,' CEO Stephane Bancel said in the statement. The department of health and human services, under the leadership of long-time vaccine sceptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their Covid booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that Covid vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunisation schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original Covid vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe Covid-19 for the upcoming immunisation campaign. The FDA approved Novavax's Covid vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviours like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-Covid combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot.

Steel and aluminum tariffs raised to 50pc as Trump highlights Nippon investment
Steel and aluminum tariffs raised to 50pc as Trump highlights Nippon investment

Malay Mail

time10 hours ago

  • Malay Mail

Steel and aluminum tariffs raised to 50pc as Trump highlights Nippon investment

WASHINGTON, May 31 — US President Donald Trump said yesterday that he would double steel and aluminum import tariffs to 50 per cent from next week, the latest salvo in his trade wars aimed at protecting domestic industries. "We're going to bring it from 25 percent to 50 percent, the tariffs on steel into the United States of America," he said while addressing workers at a US Steel plant in Pennsylvania. "Nobody's going to get around that," he added in the speech before blue-collar workers in the battleground state that helped deliver his election victory last year. Shortly after, Trump wrote in a Truth Social post that the elevated rate would also apply to aluminum, with the new tariffs "effective Wednesday, June 4th." Since returning to the presidency in January, Trump has imposed sweeping tariffs on allies and adversaries alike in moves that have rocked the world trade order and roiled financial markets. He has also issued sector-specific levies that affect goods such as automobiles. He defended his trade policies, arguing that tariffs helped protect US industry. He added that the steel facility he was speaking in would not exist if he had not also imposed duties on metals imports during his first administration. Devil in the details On Friday, Trump touted a planned partnership between US Steel and Japan's Nippon Steel, but offered few new details on a deal that earlier faced bipartisan opposition. He stressed that despite a recently announced planned partnership between the American steelmaker and Nippon Steel, "US Steel will continue to be controlled by the USA." He added that there would be no layoffs or outsourcing of jobs by the company. Upon returning to Washington yesterday, Trump told reporters he had yet to approve the deal. "I have to approve the final deal with Nippon, and we haven't seen that final deal yet, but they've made a very big commitment," Trump said. Last week, Trump said that US Steel would remain in America with its headquarters to stay in Pittsburgh, adding that the arrangement with Nippon would create at least 70,000 jobs and add US$14 billion to the US economy. Trump in Pennsylvania said that as part of its commitment, Nippon would invest US$2.2 billion to boost steel production in the Mon Valley Works-Irvin plant where he was speaking. Another US$7 billion would go towards modernizing steel mills, expanding ore mining and building facilities in places including Indiana and Minnesota. A proposed US$14.9 billion sale of US Steel to Nippon Steel had previously drawn political opposition from both sides of the aisle. Former president Joe Biden blocked the deal on national security grounds shortly before leaving office. There remain lingering concerns over the new partnership. The United Steelworkers union (USW) which represents thousands of hourly workers at US Steel facilities said after Trump's speech that it had not participated in discussions involving Nippon Steel and the Trump administration, "nor were we consulted." "We cannot speculate about the meaning of the 'planned partnership,'" said USW International President David McCall in a statement. "Whatever the deal structure, our primary concern remains with the impact that this merger of US Steel into a foreign competitor will have on national security, our members and the communities where we live and work," McCall said. "The devil is always in the details," he added. Trump had opposed Nippon Steel's takeover plan while on the election campaign trail. But since returning to the presidency, he signaled that he would be open to some form of investment after all. — AFP

US FDA approves Moderna's next-gen mNEXSPIKE Covid vaccine for adults 65 and older, high-risk individuals
US FDA approves Moderna's next-gen mNEXSPIKE Covid vaccine for adults 65 and older, high-risk individuals

Malay Mail

time11 hours ago

  • Malay Mail

US FDA approves Moderna's next-gen mNEXSPIKE Covid vaccine for adults 65 and older, high-risk individuals

Moderna Covid vaccine approved for those 12-64 with risk factors Moderna expects mNEXSPIKE to be ready for 2025-2026 season Vaccine easier to distribute in developing countries WASHINGTON, May 31 — The US Food and Drug Administration has approved Moderna's next-generation Covid-19 vaccine for everyone aged 65 and above, the company said today, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement. The company said it expects to have the vaccine, called mNEXSPIKE, available for the 2025-2026 respiratory virus season. 'The FDA approval of our third product, mNEXSPIKE, adds an important new tool to help protect people at high risk of severe disease from Covid-19,' CEO Stephane Bancel said in the statement. The Department of Health and Human Services, under the leadership of long-time vaccine skeptic Robert F. Kennedy Jr., is tightening regulatory scrutiny on vaccines. The FDA said on May 20 it planned to require drugmakers to test their Covid booster shots against an inert placebo in healthy adults under 65 for approval, effectively limiting them to older adults and those at risk of developing severe illness. The Moderna vaccine can be stored in refrigerators rather than freezers, to offer longer shelf life and make distribution easier, especially in developing countries where supply-chain issues could hamper vaccination drives. The Centers for Disease Control and Prevention, which Kennedy also oversees, said on Thursday that Covid vaccines remain an option for healthy children when parents and doctors agree that it is needed, stopping short of Kennedy's announcement days earlier that the agency would remove the shots from its immunisation schedule. The CDC announcement eases investor concern to some extent, analysts say, as it keeps the existing framework for older adults and at-risk people who generally seek out the shots. FDA leaders have said 100 million to 200 million Americans would still be eligible for annual shots. Moderna is betting on its newer messenger RNA vaccines as it grapples with waning demand for its original Covid vaccine Spikevax and lower-than-expected uptake of its respiratory syncytial virus vaccine. The approval for mNEXSPIKE was based on late-stage trial data, which showed the shot was not inferior in efficacy compared to Spikevax in individuals aged 12 years and older. The shot also showed superior efficacy compared to Spikevax in adults 18 years of age and older in the study. Kennedy has kickstarted a major overhaul of health departments, laying off thousands of employees to align with President Donald Trump's goal of dramatically shrinking the federal government. This has further ignited worries about potential disruptions to the regulatory review of treatments and vaccines. The CDC's outside panel of vaccine experts in April discussed recommending the booster shots only for populations at risk of severe Covid-19 for the upcoming immunisation campaign. The FDA approved Novavax's Covid vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness. Conditions that constitute additional risk range from illnesses such as diabetes and heart disease to behaviours like physical inactivity and substance abuse, according to the CDC. While Moderna's shots, as well as Pfizer-BioNTech's Comirnaty, are mRNA-based, Novavax's vaccine is protein-based and takes longer to manufacture. Moderna this month withdrew an application seeking approval for its flu-and-Covid combination vaccine candidate to wait for efficacy data from a late-stage trial of its influenza shot. — Reuters

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store